We speculated that this elevated level of SLC22A4 promotes the uptake of imatinib in CML cells, thereby enhancing the cellular response to imatinib treatment in CML. This evidence concerns the gene SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive.